Complete Genomics deciphers 14 human genomes

September 9, 2009 By Scott Duke Harris

Complete Genomics, a Mountain View, Calif., startup, has announced that it had deciphered 14 full human genomes for customers that include pharmaceutical giant Pfizer and leading medical research institutes, a significant step for an industry whose work could revolutionize health care.

"We probably doubled the known genomes in the world," said Clifford Reid, co-founder and CEO of Complete Genomics. "This is just the beginning. The real action starts later next year. Then you'll start to see important medical results come out."

Complete Genomics is among several companies that are generating excitement about the potential for research. In Complete Genomics' case, the company says its technology and economies of scale have enabled it to cut the cost of sequencing a genome from about $250,000 to $4,000.

And executives at Pacific Biosciences, a Menlo Park, Calif., startup backed by $260 million in investments, are predicting that their genetic-sequencing technology will be delivered next year and could lead to advances that within a few years could turn genomic profiles into a standard part of a physical exam.

All life-forms carry a genome, a full strand of that is a reflection of its hereditary traits. Deciphering, or "sequencing," a genome generates a vast amount of raw data that researchers are trying to decode in a quest to understand how heredity influences various maladies. Reid said he expects the company to produce 10,000 sequenced genomes by the end of 2010, greatly enhancing the potential for meaningful discovery. "It's all about scale. Sequencing one is a scientific curiosity," he said.

Complete Genomics offered no names or descriptive information about the persons whose genomes were sequenced. The genomes, Reid said, are being studied by customers to validate the company's technology and for small-scale studies of four types of cancer (breast, lung, colorectal and melanoma), HIV and schizophrenia, the companies said. In the cancer studies, Complete Genomics said, researchers are comparing patients' tumor genome with their noncancerous genome in search of variations that provide insights into the cause or spread of the disease.

The aim is to use this previously unavailable whole data to accurately characterize the tumor and identify its vulnerabilities, which in turn can be used to design more effective therapies. The customers include the Flanders Institute for Biotechnology, Duke University, Brigham & Women's Hospital, the HudsonAlpha Institute for Biotechnology, the Ontario Institute for Cancer Research, the Institute for Systems Biology and Broad Institute of MIT, and Harvard.

These are some of more than a dozen customers using Complete Genomics technology to conduct small pilot projects, each composed of five to 10 genomes, the company said.

Complete Genomics' technology has been tested and verified by Harvard researchers led by George M. Church, who has been a member of the company's scientific advisory board. In a press release, Church said, "Complete Genomics' technology can clearly deliver high-quality genomic data, which compare favorably with other published results, and at a low cost."

(c) 2009, San Jose Mercury News (San Jose, Calif.).
Visit Mercury Center, the World Wide Web site of the Mercury News, at
Distributed by McClatchy-Tribune Information Services.

Explore further: Large scale flu virus sequencing completed

Related Stories

New genome sequencing targets announced

July 24, 2006

The U.S. National Human Genome Research Institute has announced several new sequencing targets, including the northern white-cheeked gibbon.

Johns Hopkins to participate in 1000 Genomes Project

January 22, 2008

Researchers at the McKusick-Nathans Institute of Genetic Medicine (IGM) at Johns Hopkins will join other national and international scientists in the 1000 Genomes Project, an ambitious effort that will involve sequencing ...

Recommended for you

New discovery challenges long-held evolutionary theory

October 19, 2017

Monash scientists involved in one of the world's longest evolution experiments have debunked an established theory with a study that provides a 'high-resolution' view of the molecular details of adaptation.

Gene editing in the brain gets a major upgrade

October 19, 2017

Genome editing technologies have revolutionized biomedical science, providing a fast and easy way to modify genes. However, the technique allowing scientists to carryout the most precise edits, doesn't work in cells that ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.